Parainfluenza
6 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study (NCT03808922) | Ansun Biopharma, Inc. | 2019-05-23 |
| Specific Respiratory Infections as Triggers of Acute Medical Events (NCT02984280) | University College, London | 2016-09-01 |
| A Phase II, Randomized, Double-blind, Placebo-controlled Study to Examine the Effects of DAS181 in Immunocompromised Subjects With Lower Respiratory Tract Parainfluenza Infection on Supplemental Oxygen (NCT01644877) | Ansun Biopharma, Inc. | 2014-03-01 |
| An Open Label Study to Examine the Effects of DAS181 Administered by Dry Powder Inhaler (DPI) or Nebulized Formulation in Immunocompromised Subjects With Parainfluenza (PIV) Infection (NCT01924793) | Ansun Biopharma, Inc. | 2013-08-01 |
| A Study to Assess the Safety of Live Intranasal Sendai Virus Vaccine in Children and Toddlers (NCT00186927) | St. Jude Children's Research Hospital | 2005-05-05 |
Track Parainfluenza automatically
Every clearance here is in the API, with alerts when new ones post.